Innovus Pharmaceuticals Reports Preliminary Q1 2019 Sales Revenue of Approximately $5.4 million

Preliminary Quarterly Revenue Increase of 12.8% Comparable to 2018
Fourth Quarter and Increase of 18.0% Comparable to 2018 First Quarter

SAN DIEGO–(BUSINESS WIRE)–Innovus Pharmaceuticals, Inc., (“Innovus Pharma”) (OTCQB: INNV), today
announced preliminary first quarter 2019 net revenue is estimated to be
$5.4 million or an approximate 12.8% increase from the fourth quarter of
2018 and 18.0% increase from the first quarter of 2018. Innovus Pharma’s
first quarter 2019 anticipated revenue results are preliminary and based
on the most current information available and are subject to completion
of the condensed consolidated financial statements for the first quarter
of 2019, which are to be filed with the SEC no later than May 15, 2019.

“We continue to execute on our controlled growth and profitability plan
with focusing our growth in profitable sales channels only,” stated
Bassam Damaj, President and Chief Executive Officer of Innovus Pharma.
“The market should also expect to see a more robust ANDA OTC pipeline
very soon,” continued Dr. Damaj.

The Company will host a conference call on Wednesday, May 15, 2019 at
4:15 p.m. ET/1:15 p.m. PT to discuss the financial results and recent
business developments. To participate in the call, please dial
1-877-883-0383 for domestic callers or 1-412-902-6506 for international
callers or 1-877-885-0477 for Canadian callers. Participant Elite Entry
Number: 0678670. A replay of the call will be available for 30 days. To
access the replay, dial 1-877-344-7529 domestically or 1-412-317-0088
internationally or 1-855-669-9658 for Canada and reference Replay Access
Code: 10131471. The replay will be available shortly after the end of
the conference call.

About Innovus Pharmaceuticals, Inc.

Headquartered in San Diego, Innovus Pharma is an emerging OTC consumer
goods and specialty pharmaceutical company engaged in the
commercialization, licensing and development of safe and effective
non-prescription medicine and consumer care products to improve men’s
and women’s health and vitality and respiratory diseases. Innovus Pharma
delivers innovative and uniquely presented and packaged health solutions
through its (a) OTC medicines and consumer and health products, which we
market directly, (b) commercial partners to primary care physicians,
urologists, gynecologists and therapists, and (c) directly to consumers
through our on-line channels, retailers and wholesalers. The Company is
dedicated to be a leader in developing and marketing new OTC and branded
Abbreviated New Drug Application (“ANDA”) products. The Company is
actively pursuing opportunities where existing prescription drugs have
recently, or are expected to, change from prescription (or Rx) to OTC.

For more information, go to www.innovuspharma.com;
www.zestra.com;
www.ejectdelay.com;
www.myvesele.com;
www.urivarx.com;
www.sensumplus.com;
www.myandroferti.com;
www.beyondhumantestosterone.com;
www.getbeyondhuman.com;
www.trybeyondhuman.com;
www.recalmax.com;
www.prostagorx.com;
www.fluticare.com;
www.allervarx.com;
and www.apeaz.com.

Innovus Pharma’s Forward-Looking Safe Harbor

Statements under the Private Securities Litigation Reform Act, as
amended: with the exception of the historical information contained in
this release, the matters described herein contain forward-looking
statements that involve risks and uncertainties that may individually or
mutually impact the matters herein described for a variety of reasons
that are outside the control of the Company, including, but not limited
to, its financial results, projected revenues, projected online
subscribers and other customers, estimated markets for its products, and
statements about achieving its other corporate and business development,
growth, commercialization, financial and staffing objectives. Readers
are cautioned not to place undue reliance on these forward-looking
statements as actual results could differ materially from the
forward-looking statements contained herein. Readers are urged to read
the risk factors set forth in the Company’s most recent filing on Form
S-1, annual report on Form 10-K, subsequent quarterly reports filed on
Form 10-Q and other filings made with the SEC. Copies of these reports
are available from the SEC’s website or without charge from the Company.

Contacts

Randy Berholtz
Innovus Pharma Investor Relations
Tel: +1 858
249 7865
[email protected]